HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.
HLA types, especially HLA-DR3, are associated with the development of toxic reactions in patients with rheumatoid arthritis after treatment with gold or D-penicillamine. In this study, after treatment with sulphasalazine, leucopenia was observed in three patients, who all had a history of leucopenia after previous gold treatment. The HLA types of these patients did not include HLA-DR3; the two patients developing mild leucopenia had HLA-DR2 and the one developing agranulocytosis had HLA-DR4.
Bliddal
H
H
Department of Rheumatology, Bispebjerg Hospital, Copenhagen, Denmark.
Eiberg
B
B
Helin
P
P
Svejgaard
A
A
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006052:Gold Sodium Thiomalate / Q000009:adverse effects*; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced*; D008875:Middle Aged; D012460:Sulfasalazine / Q000009:adverse effects*
D006684:HLA-DR Antigens; D006052:Gold Sodium Thiomalate; D012460:Sulfasalazine